InvestorsHub Logo
Followers 30
Posts 4075
Boards Moderated 0
Alias Born 07/25/2007

Re: DewDiligence post# 2893

Sunday, 03/10/2024 12:01:12 PM

Sunday, March 10, 2024 12:01:12 PM

Post# of 2947

ENTA’s rationale for securing additional IP in HBV/HDV could be to seek royalties on GILD’s Hepludex rather than to support ENTA’s own HBV program.



Dew, could you explain how they could get royalties from patents they just filed?
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent ENTA News